RestructuringAug 5, 2026, 04:32 PM
STERIS Announces Restructuring Plan; Q1 Revenue +7%, Adj. EPS $2.59
AI Summary
STERIS plc announced a targeted restructuring plan to consolidate manufacturing and distribution for formulated chemistries to a new Center of Excellence in North Carolina, involving estimated pre-tax charges of $55 million to $70 million. Concurrently, the company reported strong fiscal 2027 first quarter results, with revenue increasing 7% to $1.5 billion and adjusted diluted EPS rising to $2.59. While full-year revenue and adjusted EPS guidance were reiterated, capital expenditures were increased to $450 million and free cash flow guidance was lowered to $800 million due to the investment.
Key Highlights
- Targeted restructuring plan announced for new Formulated Chemistries Center of Excellence in North Carolina.
- Estimated total pre-tax restructuring charges of $55 million to $70 million, with completion by fiscal 2030.
- Fiscal 2027 first quarter revenue increased 7% to $1.5 billion.
- Adjusted diluted EPS for Q1 FY27 increased to $2.59 from $2.34 in the prior year.
- Healthcare segment revenue grew 8% to $1.05 billion.
- Fiscal 2027 capital expenditures now anticipated at $450 million, up from prior expectations of $375 million.
- Fiscal 2027 free cash flow now expected at $800 million, down from prior expectations of $850 million.
- Reiterated fiscal 2027 revenue growth guidance of 7-8% and adjusted EPS of $11.10 to $11.30.
Price Impact
More from STE